<img height="1" width="1" src="https://www.facebook.com/tr?id=914352225269004&amp;ev=PageView &amp;noscript=1">
Brand New Medical Study

Potential New Treatment for Lung Fibrosis

💡 A study exploring a new treatment for reducing persistent cough
💡 Spaces available for 12 new patients

Who can take part in this study?
Male and female participants with a diagnosis of Idiopathic pulmonary fibrosis (IPF) with a cough that started in the last seven (7) years.

about_1
📝 Registration Form
If you take part in the research study you will receive:

Reimbursement of costs

For out-of-pocket expenses, such as travel and meals etc.

Free study-related medical care

All medical care required as part of the research project will be provided to you free-of-charge.

No overnight stays!

All study visits are out-patient only.

🏥 Study Guide

Who can take part in this study?

Male and female participants with a diagnosis of Idiopathic pulmonary fibrosis (IPF) with a cough that started in the last seven (7) years.

Who is unable take part in this study?

  • Anyone who participated in a clinical research study recently.
  • Anyone who currently has significant airways obstruction.
  • Anyone who has clinical evidence of active infection, including, but not limited to:
    • Bronchitis
    • Pneumonia
    • Sinusitis
    • Urinary tract infection
    • Cellulitis
  • Anyone who has a history of cancer within the last 2 years with the exception of:
    • Basal cell carcinoma (BCC and SCC if diagnosed more than 6 months ago)
    • Chronic lymphocytic leukaemia
  • Women who are pregnant, or lactating, or intending to become pregnant before participating in this study during the study and within (5 half- lives plus 30 days) after the last dose of the study drug; or intending to donate ova during such a time period.

How long will the study take?

If you agree to take part, and the study is suitable for you, your participation in the study is expected to last up to 15 weeks. This includes:
  • A screening period, of up to 2 weeks
  • A study treatment period of 12 weeks (3 months), requiring at least 5 clinic visits and a final visit

What is the purpose of this study?

IPF is a disease that causes scarring in the lungs that leads to shortness of breath and a persistent cough.

The purpose of this research study is to test the effectiveness of the study drug in reducing cough and improving quality of life in people with a persistent cough due to IPF. The study drug has an established safety record and has been used in France and Japan to treat other ailments.

Where is my nearest study site?

Here is a map of all of the sites who are currently recruiting for this study:

What if I have other questions about the study?

We are here for you, so click or tap this button to send an email to our Patient Experience team:

 

Lung Foundation Australia have published some additional resources which you may find useful:

📝 Registration Form